Member Info for EmeraldCarrots

U sure Illumina won't bid for Angle Plc?!!!!

From Illumina's web site:-

https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf

Hello.

Moab & Thompi.

If you do a search on google for "what can ctdna tell you about a cancer?" you get this:-

"ctDNA can be used to test for changes in biomarker status which can lead to a change in treatment. ctDNA can be measured in blood to identify the presence of residual cancer cells after surgery or to monitor for cancer recurrence after successful treatment.".

Moab.

You stated:- "The ctDNA test is not aimed at finding actionable varients as incomplete fragments of DNA may be either useless or unhelpful because they are a tiny, tiny fragment of all the DNA that is in plasma as a result of cell apoptosis.".

I see. So the ctdna analysis of the blood plasma is more general test but not specific enough to find actionable DNA varients? Thanks for correcting me there. I only want to find the facts, not distort them.

Then you stated this: "I do not deny the contents of the RNS, but it is bleedingly obvious that more info is going to come from an intact tumour cell than an incomplete shred of DNA in plasma.".

I'm glad you agree live CCT's offer a lot more information, ***including sometimes actionable DNA varients*** as Angle have stated in their RNS's. This is why IMHO Companies like Illumina should be adding to their offering analysing the LIVE circulating tumour cells (CTC's). As you are aware Angle's Parsortix machine can catch LIVE intact CCT's which can be tested by the likes of Illumina's hardware to find if they contain any actionable DNA varients. These DNA varients might then be targeted by modern cancer treatment methods. This is why the sp spiked to 37p on 4th Jan. Very good. In conclusion it seems totally obvious to me that all the Companies who currently sell CtDna analysis machinines will want to add the analysys of CCT's!!!!!!!!!!!!!!!!! The next RNS should be interesting !

All IMHO.

Moab.

In reply to your post.

1, What original question?

2. Why have you not answered the subject title question above. If there is a valid reason then I'd like to know. Even if it is bad news!

3. Angle's RNS's of 4th Jan and 20th Jan are basically saying they have found "actionable DNA varients" in LIVE circulating tumour cells (CTC's) that were NOT found when the same patients blood plasma DNA fragments were tested (the CtDNA). Do you deny that is what the RNS says? Actionable DNA, as I understand it, is DNA that, if found in the cancer can be targeted by certain treatments? Do you deny this? You may have mis-understood my posts. This discovery was only anounced on 4th Jan! I was trying to say this. IN THE FUTURE, the likes of the Illumina system might be used to find any actionable DNA varients in both the CtDna and the CCT's. Those actionable variants might then be targeted with treatments. Note the information from CtDNA analysis is already currectly used to guide clinicians as I understand it. Adding the CCT analysis seems the next logical step, and that seems to be what Angle are suggesting. That is why, as they said in the RNS, they are discussing this with Illumina.

All IMHO.

15 mins to get in if you want.

If positive news leaks over the weekend the sp will start Moday way higher than 0.35p IMHO.

I think early next week the sp will break .40p.

Next Thursday (21st). They will have a good idea well before than I suspect. Next Wednesday??

This dip may be the lowest it goes........... for years!!

Moab.

If I had metastasized cancer (spread, or in the blood supply trying to re-seed) and I had for example an Illumina CtDNA test so the clinician could decide what treatment I should have I would want it to be as accurate as possible. The CtDNA test is to find actionable DNA variants. These are usually found by analysing DNA fragments of dead cells which naturally and up in blood plasma before being excreted. Some of these fragments are from the cancer tumour. Some treatments can TARGET these variants (therefore the cancer) slowing down the spread, possibly stopping it. Angle have shown that sometimes there are STILL actionable DNA variants in circulating cancer cells WHEN NONE ARE FOUND in the standard CtDNA test!!!!!!! Therfore Angle are suggesting ALL the Companies IN THE WORLD that already offer CtDNA analysis of the DNA fragments in blood plasma ALSO offer the same analysis of the circulating cancer cells. Clearly if a circulating cancer cell is STILL in the blood supply and it has actionable DNA variants that might be TARGETED by treatment it is rather important, to say the least!!

Clearly the stock market totally fails at the moment to appreciate this!!

Once Angle get the firrst Molecular analysis Co. on board this will massively change IMHO.

All IMHO.

Looks like the market has decided they are way undervalued.

Moab.

Please filter my posts. I have no interest at all in anything you say.

I find it totally astonishing that Molecular analysis Co's in the World, including Illumina Inc. of USA, seemed to be totally unaware that DNA sequencing CtDNA does NOT give the full picture of a patients cancer that has metastasized. Angle's RNS's dated 4th Jan and 22nd Jan show that also DNA sequencing LIVE circulating tumour cells (that Angles's Parsortix machine can catch in a matter of hours) can sometimes find actionable DNA variants in the cct's! Actionable DNA variants NOT FOUND in the CtDNA! These actionable DNA variants can be targeted for treatment by ****some treatments currently available****. Therefore clearly some patients with actionable DNA in their cancer have, and are still being missed.

Illumina and the other Co's in this field really need to sort this out.

- I'm sure Angle Plc will be willing to discuss ways forward with this.

All IMHO.

Ikhan1284.

"It's totally luck 😹 I will buy 50 million shares and see what happens".

======================

I'm waiting to see this.

This! LOL!

Hello.

Big rise for IAG, no news I can find????

One of these Molecular analysis Co's has simply got to offer this soon, even as an optional extra. It could save lives don't forget. DNA sequencing CtDNA does NOT give the full picture as to what actionable DNA varients there are in a patient. See Angle's RNS's dated 4th Jan and 22nd Jan..

First of all I find it difficult to believe a Company like Illumina, valued on NASDAQ at over $5 BILLION was unaware that analysing (DNA sequencing) circulating tumour cells (cct's), can give IMPORTANT additional information over and above the standard CtDNA analysis they offer. Surely the knew already? Note they do not seem to have a product to catch cct's as Angle and a few other co's do. Hmm. It's safe to say they do now as of 4th January, see Angles RNS announcement in which they actually used an Illumina product to get the results. Also they mention they were talking to Illumina (and others) about the results. I suspect Illumina and other Molecular analysis Co's will soon be asked some awkward questions as to why they either did not know, or why they have suppressed it...............................

I know one thing. If I had cancer that had spread and found out my clinician could have got more information but some large Co's could have helped but they were more concerned about profit I would not be happy.

All IMHO.

One of these Molecular analysis Co's has simply got to offer this soon, even as an optional extra. It could save lives don't forget. DNA sequencing CtDNA does NOT give the full picture as to what actionable DNA varients there are in a patient. See Angle's RNS's dated 4th Jan and 22nd Jan.

First of all I find it difficult to believe a Company like Illumina, valued on NASDAQ at over $5 BILLION was unaware that analysing (DNA sequencing) circulating tumour cells (cct's), can give IMPORTANT additional information over and above the standard CtDNA analysis they offer. Surely the knew already? Note they do not seem to have a product to catch cct's as Angle and a few other co's do. Hmm. It's safe to say they do now as of 4th January, see Angles RNS announcement in which they actually used an Illumina product to get the results. Also they mention they were talking to Illumina (and others) about the results. I suspect Illumina and other Molecular analysis Co's will soon be asked some awkward questions as to why they either did not know, or why they have suppressed it...............................

I know one thing. If I had cancer that had spread and found out my clinician could have got more information but some large Co's could have helped but they were more concerned about profit I would not be happy.

All IMHO.

Surprised if Oil Co's with wells in Alaska are interested. Clearly if 88E do get a decent flow result the value of their prospect acreage woud be hundreds of millions IMHO.

All IMHO.

or is someone taking the ****? lol!

LOL!